Related Experiment Videos
Structural characterization of impurities in pioglitazone
Y R Kumar1, A R Reddy, S Eswaraiah
1Dr. Reddy's Laboratories Ltd., Hyderabad, India.
Die Pharmazie
|December 14, 2004
Summary
Three key impurities in pioglitazone bulk drug were identified and characterized using advanced analytical techniques. Understanding these impurities is crucial for drug safety and quality control.
Area of Science:
- Pharmaceutical Chemistry
- Analytical Chemistry
- Organic Chemistry
Background:
- Pioglitazone is an important antidiabetic medication.
- Controlling impurities in bulk drug substances is critical for pharmaceutical quality and patient safety.
- Previous characterization of pioglitazone impurities may be incomplete.
Purpose of the Study:
- To identify and characterize prominent impurities in pioglitazone bulk drug.
- To elucidate the structures of these impurities using spectroscopic methods.
- To discuss the synthesis of the identified impurities.
Main Methods:
- Reversed-phase High-Performance Liquid Chromatography (RP-HPLC) for impurity detection and quantification.
- Isolation of impurities from enriched mother liquor samples.
- Structural characterization using Nuclear Magnetic Resonance (NMR) spectroscopy (1H, 13C, DEPT), Mass Spectrometry (MS), and Infrared (IR) spectroscopy.
Main Results:
- Three main impurities (I-III) were detected in pioglitazone bulk drug at concentrations up to 0.1%.
- Impurity I was identified as 5-(4-hydroxybenzyl)-1,3-thiazolidine-2,4-dione.
- Impurity II was identified as 5-(4-fluorobenzyl)-1,3-thiazolidine-2,4-dione.
- Impurity III was identified as 2-[2-(4-bromophenoxy) ethyl-5-ethyl pyridine.
Conclusions:
- The structures of three significant pioglitazone impurities have been successfully elucidated.
- The findings provide essential data for quality control and impurity profiling of pioglitazone.
- Further studies on the synthesis and toxicological profiles of these impurities may be warranted.